Goldman Sachs Group Inc Nrx Pharmaceuticals, Inc. Transaction History

Goldman Sachs Group Inc

  • $605 Billion
  • Q3 2024

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

May 14, 2024
SELL
$0.2 - $8.07 $178 - $7,206
-893 Reduced 3.97%
21,619 $16,000
Q3 2022

Nov 10, 2022
SELL
$0.2 - $8.07 $178 - $7,206
-893 Reduced 3.97%
21,619 $0
Q2 2022

May 14, 2024
BUY
$0.51 - $2.42 $11,481 - $54,479
22,512 New
22,512 $14,000
Q2 2022

Aug 15, 2022
BUY
$0.51 - $2.42 $621 - $2,947
1,218 Added 5.72%
22,512 $14,000
Q1 2022

May 16, 2022
BUY
$2.45 - $5.04 $4,103 - $8,442
1,675 Added 8.54%
21,294 $52,000
Q4 2021

Feb 14, 2022
BUY
$4.5 - $11.91 $88,285 - $233,662
19,619 New
19,619 $94,000

Others Institutions Holding NRXP

# of Institutions
2
Shares Held
17.4K
Call Options Held
0
Put Options Held
0
View Full List

About NRX Pharmaceuticals, Inc.

NRXP Quotes by TradingView
  • Ticker NRXP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 67,641,296
  • Market Cap $81.2M
  • Description
  • NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-10...
More about NRXP
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email